Baynes Roy D., an insider at Natera Inc (NTRA), acquired 23,471 shares of the company on November 18, 2025, at a price of $40.93 per share, resulting in a total transaction value of approximately $961,000. Following this purchase, Baynes holds a total of 23,471 shares in Natera.
Natera, a biotechnology firm headquartered in Austin, Texas, specializes in genetic testing services. The company employs 4,424 full-time staff and leverages its cfDNA technology platform to offer various diagnostic tests, including non-invasive prenatal testing (Panorama) and cancer care assays (Signatera). With a market capitalization of $30.7 billion, Natera reported a trailing twelve months (TTM) earnings per share of -$2.28.
Insider buying often serves as a positive signal, as executives typically possess insights into their company's internal operations. However, investors should consider that such transactions may stem from various personal or regulatory motivations.
The transparency provided by insider transactions, which must be reported to the SEC, allows investors to gauge the sentiment of company executives. While this single transaction reflects one insider's perspective, examining broader patterns across multiple insiders may yield more comprehensive insights into the company's outlook. Natera's upcoming earnings reports are scheduled for May 6, 2026, and August 5, 2026, with estimated EPS of -$0.50 and -$0.54, respectively.